Form 4: Immunic CEO Erik Lundgren Receives 1M Share Option Grant
Statement of Changes in Beneficial Ownership
Immunic, Inc. CEO Erik Lundgren was granted 1,000,000 stock options with an exercise price of $13.05.
Summary
- CEO Erik Lundgren received a grant of 1,000,000 stock options on May 22, 2026.
- The options have an exercise price of $13.05 per share.
- The options expire on May 22, 2036.
- Vesting is time-based: 25% vests on May 22, 2027, with the remaining 75% vesting in 36 equal monthly installments.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation, which is standard for a public company.
Positives
- Alignment of executive interests with long-term shareholder value through equity-based compensation.
Negatives
- Potential for future shareholder dilution upon the exercise of the 1,000,000 stock options.
Risks
- Vesting is contingent upon the Reporting Person remaining an employee of Immunic, Inc. in good standing.
Future Outlook
The grant serves as a long-term incentive for the CEO, contingent on continued employment and performance over the next four years.
Industry Context
StockSavvy.ai notes that large equity grants to CEOs in the biotechnology sector are standard practice to ensure leadership retention and align management with long-term clinical and commercial milestones.
Comparison to Industry Standards
- The four-year vesting schedule is consistent with standard corporate governance practices for executive equity compensation in the U.S. biotech industry.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | N/A | Erik Lundgren | 06/01/2026 | Appointment to Board of Directors |
Stakeholder Impact
- Shareholders may experience dilution if these options are exercised in the future.
Next Steps
- Vesting of 25% of options on May 22, 2027.
- Continued monthly vesting of remaining options through May 2030.
Key Dates
| Date | Description |
|---|---|
| 05/22/2026 | Date of the stock option grant transaction. |
| 05/22/2027 | Initial 25% vesting date for the stock options. |
| 06/01/2026 | Date the Reporting Person became a director and Section 16 insider. |
| 05/22/2036 | Expiration date of the stock options. |
Keywords
Immunic, IMUX, CEO, Stock Options, Executive Compensation, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.